Original articleClinical–prostateCombining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer☆
Introduction
More than 20 years after introduction of PSA into clinical practice, substantial gains in prostate cancer mortality reduction have been realized, but concurrent limitations in the performance of PSA in selecting patients for prostate biopsy have persisted. These limitations have been further underscored by recently reported results from the European Randomized Study of Screening for Prostate Cancer (ERSPC) and Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), which together indicate a continued need to improve upon serum PSA as our leading tool for prostate cancer early detection [1], [2], [3], [4], [5], [6].
The need for additional biomarkers that supplement PSA is reflected by the number of ongoing studies in this field. Amongst numerous experimental biomarkers for prostate cancer early detection, prostate cancer gene 3 (PCA3) [7] and recurrent gene fusions involving TMPRSS2 and ETS family members (such as TMPRSS2:ERG) [8] have shown promising results in preliminary studies and can be detected in post-DRE [9], [10], [11] urine specimens that are suitable for possible use in clinical diagnostic strategies. One possible drawback of new molecular targets for early detection such as PCA3 or TMPRSS2:ERG fusion could be that they may only identify certain subgroups of cancer cases. In this context, one approach for optimizing performance of such biomarkers in predicting prostate cancer diagnosis is to develop models that combine different biomarkers to generate clinically useful, ‘multiplex’ algorithms for identifying candidates for prostate biopsy based on results of multiple biomarker assays combined with PSA test results.
In this study, we sought to verify the association of prostate cancer with detection in urine of TMPRSS2:ERG gene fusion, PCA3, and investigated how these biomarkers may be combined with serum PSA levels to develop clinically practical algorithms for predicting prostate cancer diagnosis.
Section snippets
Materials and methods
Urine samples were collected after attentive digital rectal exam (DRE) from 48 men undergoing prostate biopsy at 2 clinical practice sites participating in the National Cancer Institute/Early Detection Research Network biopsy cohort. Institutional Review Board approval was obtained at the collaborating institutions and informed consent was obtained from these men. Demographic and pre-biopsy clinical parameters, including age, race, history of smoking, height, weight, family history of prostate
Results
The demographic and pre-biopsy clinical parameters of 45 men from whom post-DRE urine samples were collected before prostate biopsy for these analyses and informative RNA was obtained are presented in Table 1. Fifteen (33%) men had a diagnosis of prostate cancer on biopsy of whom 7 (47%) have a Gleason 7 or higher. Of the 30 (67%) men without prostate cancer on biopsy, 5 (17%) had either atypia or prostatic intraepithelial neoplasia (PIN) or both identified on histology.
In the univariate
Comment
The performance of serum PSA as a biomarker for prostate cancer early detection is undermined by several limitations, including substantial false positive and false negative tests results because PSA is produced in benign as well as malignant prostate tissue. Hence, there is a need to identify biomarkers that are more specific for prostate cancer and that may thereby improve prospects for prostate cancer screening and early detection [5].
Recent advancements in high throughput technologies have
Conclusions
Early detection of prostate cancer is crucial in providing an effective therapy to patients. These new biomarkers can potentially fulfill this task more effectively than serum PSA alone, when used in combination. We have shown in this pilot study that TMPRSS2:ERG gene fusion and PCA3, especially in combination with serum PSA, are very attractive targets with respect to early detection of prostate cancer. Both markers can be detected in patients' urine after attentive digital rectal examination,
References (28)
- et al.
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer
Neoplasia
(2006) - et al.
Whole transcriptome amplification for gene expression profiling and development of molecular archives
Neoplasia
(2006) - et al.
Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue
Am J Pathol
(2001) - et al.
ETS gene fusions in prostate cancer: From discovery to daily clinical practice
Eur Urol
(2009) - et al.
uPM3, a new molecular urine test for the detection of prostate cancer
Urology
(2004) - et al.
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
Urology
(2007) - et al.
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial
J Natl Cancer Inst
(2005) - et al.
Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based programThe Prostate Cancer Education Council
Urology
(1996) - et al.
Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma
Cancer
(2004) - et al.
Natural history of early, localized prostate cancer
JAMA
(2004)
Screening and prostate-cancer mortality in a randomized European study
N Engl J Med
Mortality results from a randomized prostate-cancer screening trial
N Engl J Med
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors
Cancer Res
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
Science
Cited by (150)
Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential
2023, Urologic Oncology: Seminars and Original InvestigationsRNA-based biomarkers for the diagnosis, prognosis, and therapeutic response monitoring of prostate cancer
2022, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :The integration of TMPRSS2-ERG analysis with serum PSA and urinary PCA3 analyses improved the accuracy of CaP diagnosis. Simpa et al. reported TMPRSS2-ERG fusion in post-DRE urine sediment in 67% (10/15) CaP-positive cases, whereas 26 out of 30 patients without cancer were TMPRSS2-ERG fusion-negative, representing a specificity of 87% [71]. The AUC values for serum PSA alone and PCA3 were 0.72 and 0.65, respectively, whereas TMPRSS2-ERG had the highest value of 0.77.
Blood and urine biomarkers in prostate cancer: Are we ready for reflex testing in men with an elevated prostate-specific antigen?
2021, Asian Journal of UrologyCitation Excerpt :The MiPS adds TMPRSS2:ERG mRNA (in post-DRE urine) to PCA3 and serum PSA to create a risk score. Its NPV for ruling out any PCa is 90% but its NPV in ruling out clinically significant PCa is unknown, although it is likely higher than 90% [56]. Tomlins et al. [57] showed that MiPS with the PCPT risk calculator had superior predictive accuracy compared to the PCPT risk calculator alone, demonstrating an AUC of 0.779 vs. 0.707 (p<0.001) for detecting clinically significant PCa.
A piece in prostate cancer puzzle: Future perspective of novel molecular signatures
2020, Saudi Journal of Biological Sciences
- ☆
Funding was provided by NCI-EDRN CEVC U01 CA113913. SAT, AC, and MAR are listed as inventors in a patent related to diagnostic use of TMPRSS2:ERG.
- 1
These authors share first authorship.
- 2
These authors share senior authorship.